SCHEMBL12622002

SCHEMBL12622002

O=S(=O)(c1ccccc1)N1CCC2(CC1)OCCN2S(=O)(=O)c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.64
▸ HCRTR1 O43613 2/20 0.64
▸ HCRTR2 O43614 2/20 0.64
▸ ALDH1A1 P00352 4/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ CYP2D6 P10635 1/20 0.54
▸ TSHR P16473 1/20 0.52
▸ USP2 O75604 2/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12621871 0.92 GAA (0.59) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12621863 0.88 LMNA (0.62) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12626205 0.86 L3MBTL1 (0.58) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12621845 0.86 L3MBTL1 (0.65) POLBALDH1A1L3MBTL1
SCHEMBL13035969 0.86 L3MBTL1 (0.58) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12622042 0.86 L3MBTL1 (0.78) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12622049 0.86 L3MBTL1 (0.58) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12622153 0.86 POLB (0.66) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12626006 0.86 L3MBTL1 (0.58) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1
SCHEMBL12663587 0.85 HCRTR1 (0.55) POLBHCRTR1HCRTR2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-11385221-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2022-07-12 — — US disclosed
WO-2022098700-A1 INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 CASSAVA SCIENCES, INC. (US) 2022-05-12 — — WO disclosed
US-20210389298-A1 Alzheimer's Disease Assay in a Living Patient PAIN THERAPEUTICS, INC. (US) 2021-12-16 — — US disclosed
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. 2021-04-01 — — US disclosed
EP-3791875-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS Pain Therapeutics, Inc. (US) 2021-03-17 — — EP disclosed
US-10760052-B2 Method of inhibiting tau phosphorylation Cassava Science, Inc. (US) 2020-09-01 — — US disclosed
US-20190271686-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT PAIN THERAPEUTICS, INC. 2019-09-05 — — US disclosed
US-10363239-B2 Method for inhibiting growth of cancer cells PAIN THERAPEUTICS (US) 2019-07-30 — — US disclosed
US-8580808-B2 Filamin A-binding anti-inflammatory analgesic Pain Therapeutic, Inc. (US) 2013-11-12 — — US disclosed
US-8580808-B2 Filamin A-binding anti-inflammatory analgesic Pain Therapeutic, Inc. (US) 2013-11-12 — — US disclosed
US-20110105484-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105484-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105547-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105547-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20100280057-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A BURNS BARBIER LINDSAY 2010-11-04 — — US disclosed
US-20100280057-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A BURNS BARBIER LINDSAY 2010-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, FPR1 POLB 3374/4885HCRTR1 4172/4885HCRTR2 4089/4885
US-20110105484-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC FLNA, FLNB, OPRK1 POLB 2825/4885HCRTR1 3537/4885HCRTR2 3420/4885
US-10363239-B2 Method for inhibiting growth of cancer cells FLNA, FLNB, FSCN1 POLB 2667/4885HCRTR1 3430/4885HCRTR2 3778/4885
US-20110105547-A1 FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC FLNA, FLNB, OPRK1 POLB 2825/4885HCRTR1 3537/4885HCRTR2 3420/4885
US-10760052-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT POLB 2356/4885HCRTR1 2888/4885HCRTR2 3501/4885
US-20100280057-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A FLNA, OPRL1, FLNB POLB 3806/4885HCRTR1 1651/4885HCRTR2 1832/4885
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 POLB 3278/4885HCRTR1 3880/4885HCRTR2 3876/4885
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT POLB 2356/4885HCRTR1 2888/4885HCRTR2 3501/4885
US-11661580-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT POLB 2356/4885HCRTR1 2888/4885HCRTR2 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback